Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

PIM Protein Kinase Family

  • Denis Drygin
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_7141-4



The PIM protein kinase family (PIMs) consists of three members (PIM-1, PIM-2, and PIM-3), with PIM-1 and PIM-2 having two and three isoforms, respectively, due to the use of alternative translation initiation sites. Their name is derived from the identification of its founding member pim-1 as a gene frequently activated by Moloney murine leukemia virus in T-cell lymphomas (proviral integration of Moloney virus).


Regulation of Expression and Activity

PIMs are serine/threonine kinases that have been shown to be dispensable for embryonic development, survival, or fertility, as mice deficient in all three PIM kinases are viable, although they display a significant reduction in body size, indicating that PIM kinases are important for growth. All three PIM kinases share significant (60–70 %) homology and have several common substrates; however, several targets that are unique to specific PIM family members, as in case...


Acute Myeloblastic Leukemia Refractory Multiple Myeloma CXCR4 Surface Expression Initiation Factor eIF4B Alternative Translation Initiation Site 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Brault L, Gasser C, Bracher F, Huber K, Knapp S et al (2010) PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 95:1004–1015PubMedPubMedCentralCrossRefGoogle Scholar
  2. Drygin D, Haddach M, Pierre F, Ryckman DM (2012) Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy. J Med Chem 55:8199–8208PubMedCrossRefGoogle Scholar
  3. Isaac M, Siu A, Jongstra J (2011) The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms. Drug Resist Updat 14:203–211PubMedCrossRefGoogle Scholar
  4. Morwick T (2010) Pim kinase inhibitors: a survey of the patent literature. Expert Opin Ther Pat 20:193–212PubMedCrossRefGoogle Scholar
  5. Nawijn MC, Alendar A, Berns A (2011) For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 11:23–34PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Pimera, Inc.San DiegoUSA